Histone deacetylases as targets for treatment of multiple diseases

Clinical Science

Volumn 124, Issue 11, 2013, Pages 651-662

  Tang, Jinhua ^a,b   Yan, Haidong ^a   Zhuang, Shougang ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BROWN UNIVERSITY   (United States)

Author keywords

Acetylation; Cancer; Fibrosis; Histone deacetylase; Immunomodulation; Inflammation; Metabolic disorder

Indexed keywords

3 [4 [3 (3 FLUOROPHENYL) 3 OXO 1 PROPENYL] 1 METHYL 1H PYRROL 2 YL]ACRYLOHYDROXAMIC ACID; AMIDOHYDROLASE INHIBITOR; CAPECITABINE; ENTINOSTAT; FR 276457; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MHY 218; SK 7041; SPIRUCHOSTATIN A; TRICHOSTATIN A; TUBASTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRITIS; AUTOPHAGY; CHEMICAL STRUCTURE; DEACETYLATION; DNA BINDING; DNA DAMAGE; DRUG MECHANISM; ENDOTOXEMIA; ENTERITIS; FIBROGENESIS; FIBROSING ALVEOLITIS; G1 PHASE CELL CYCLE CHECKPOINT; GENETIC ASSOCIATION; HISTONE ACETYLATION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFLAMMATION; INNATE IMMUNITY; METABOLIC DISORDER; METABOLIC REGULATION; METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ACETYLATION; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL CYCLE CHECKPOINTS; EPIGENOMICS; FIBROSIS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; IMMUNITY; IMMUNOMODULATION; METABOLIC DISEASES; NEOPLASMS;

EID: 84874688338     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20120504     Document Type: Review

References (133)

1. Khan, O. and La Thangue, N. B. (2012) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 90, 85-94
2. Inche, A. G. and La Thangue, N. B. (2006) Chromatin control and cancer-drug discovery: realizing the promise. Drug Discovery Today 11, 97-109
3. Bolden, J. E., Peart, M. J. and Johnstone, R. W. (2006) Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discovery 5, 769-784
4. Nightingale, K. P., O'Neill, L. P. and Turner, B. M. (2006) Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr. Opin. Genet. Dev. 16, 125-136
5. Roth, S. Y., Denu, J. M. and Allis, C. D. (2001) Histone acetyltransferases. Annu. Rev. Biochem. 70, 81-120
6. Thiagalingam, S., Cheng, K. H., Lee, H. J., Mineva, N., Thiagalingam, A. and Ponte, J. F. (2003) Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. N.Y. Acad. Sci. 983, 84-100
7. Fu, W., Wu, K. and Duan, J. (2007) Sequence and expression analysis of histone deacetylases in rice. Biochem. Biophys. Res. Commun. 356, 843-850
8. Verdin, E., Dequiedt, F. and Kasler, H. G. (2003) Class II histone deacetylases: versatile regulators. Trends. Genet. 19, 286-293
9. Blander, G. and Guarente, L. (2004) The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73, 417-435
10. Trapp, J. and Jung, M. (2006) The role of NAD+ dependent histone deacetylases (sirtuins) in ageing. Curr. Drug Targets 7, 1553-1560
11. Gao, L., Cueto, M. A., Asselbergs, F. and Atadja, P. (2002) Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277, 25748-25755
12. Weichert, W., Roske, A., Gekeler, V., Beckers, T., Ebert, M. P., Pross, M., Dietel, M., Denkert, C. and Rocken, C. (2008) Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 9, 139-148
13. Park, S. Y., Jun, J. A., Jeong, K. J., Heo, H. J., Sohn, J. S., Lee, H. Y., Park, C. G. and Kang, J. (2011) Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol. Rep. 25, 1677-1681
14. Osada, H., Tatematsu, Y., Saito, H., Yatabe, Y., Mitsudomi, T. and Takahashi, T. (2004) Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int. J. Cancer 112, 26-32
15. Aldana-Masangkay, G. I., Rodriguez-Gonzalez, A., Lin, T., Ikeda, A. K., Hsieh, Y. T., Kim, Y. M., Lomenick, B., Okemoto, K., Landaw, E. M., Wang, D. et al. (2011) Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. Leuk. Lymphoma 52, 1544-1555
16. Mariadason, J. M., Corner, G. A. and Augenlicht, L. H. (2000) Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer. Res. 60, 4561-4572
17. Glaser, K. B., Staver, M. J., Waring, J. F., Stender, J., Ulrich, R. G. and Davidsen, S. K. (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151-163
18. Chittur, S. V., Sangster-Guity, N. and Mccormick, P. J. (2008) Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism. BMC Genomics 9, 507
19. Seuter, S., Heikkinen, S. and Carlberg, C. (2012) Chromatin acetylation at transcription start sites and vitamin D receptor binding regions relates to effects of 1alpha,25-dihydroxyvitamin D3 and histone deacetylase inhibitors on gene expression. Nucleic Acids Res. 41, 110-124
20. Tsapis, M., Lieb, M., Manzo, F., Shankaranarayanan, P., Herbrecht, R., Lutz, P. and Gronemeyer, H. (2007) HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int. J. Biochem. Cell Biol. 39, 1500-1509
21. Baumann, P., Junghanns, C., Mandl-Weber, S., Strobl, S., Oduncu, F. and Schmidmaier, R. (2012) The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells. Br. J. Haematol. 156, 633-642
22. Mizutani, H., Hiraku, Y., Tada-Oikawa, S., Murata, M., Ikemura, K., Iwamoto, T., Kagawa, Y., Okuda, M. and Kawanishi, S. (2010) Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide. Cancer Sci. 101, 2214-2219
23. Kalin, J. H., Butler, K. V., Akimova, T., Hancock, W. W. and Kozikowski, A. P. (2012) Second-generation histone deacetylase inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells. J. Med. Chem. 55, 639-651
24. Botrugno, O. A., Robert, T., Vanoli, F., Foiani, M. and Minucci, S. (2012) Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy. Clin. Cancer Res. 18, 2436-2442
25. Lin, K. T., Wang, Y. W., Chen, C. T., Ho, C. M., Su, W. H. and Jou, Y. S. (2012) HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy. Clin. Cancer Res. 18, 4691-4701
26. Shan, Z., Feng-Nian, R., Jie, G. and Ting, Z. (2012) Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo. Asian Pac. J. Cancer Prev. 13, 3977-3982
27. Furumai, R., Ito, A., Ogawa, K., Maeda, S., Saito, A., Nishino, N., Horinouchi, S. and Yoshida, M. (2011) Histone deacetylase inhibitors block nuclear factor-κB-dependent transcription by interfering with RNA polymerase II recruitment. Cancer Sci. 102, 1081-1087
28. Lindstrom, T. M., Mohan, A. R., Johnson, M. R. and Bennett, P. R. (2008) Histone deacetylase inhibitors exert time-dependent effects on nuclear factor-κB but consistently suppress the expression of proinflammatory genes in human myometrial cells. Mol. Pharmacol. 74, 109-121
29. Bajbouj, K., Mawrin, C., Hartig, R., Schulze-Luehrmann, J., Wilisch-Neumann, A., Roessner, A. and Schneider-Stock, R. (2012) p53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells. J. Neuro-oncol. 107, 503-516
30. Pang, M., Kothapally, J., Mao, H., Tolbert, E., Ponnusamy, M., Chin, Y. E. and Zhuang, S. (2009) Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am. J. Physiol. Renal Physiol. 297, F996-F1005
31. Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70
32. Kinzler, K. W. and Vogelstein, B. (1997) Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386, 761, 763
33. Ray, B. K., Dhar, S., Henry, C. J., Rich, A. and Ray, A. (2012) Epigenetic regulation by Z-DNA silencer function controls cancer-associated ADAM-12 expression in breast cancer: cross talk between MECP2 and NFI transcription factor family. Cancer. Res. 73, 736-744
34. Tommasi, S., Zheng, A., Weninger, A., Bates, S. E., Li, X. A., Wu, X., Hollstein, M. and Besaratinia, A. (2012) Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization. Nucleic. Acids. Res. 41, 182-195
35. Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K. et al. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37, 391-400
36. Melnick, A. M., Westendorf, J. J., Polinger, A., Carlile, G. W., Arai, S., Ball, H. J., Lutterbach, B., Hiebert, S. W. and Licht, J. D. (2000) The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. Mol. Cell. Biol. 20, 2075-2086
37. Zapotocky, M., Mejstrikova, E., Smetana, K., Stary, J., Trka, J. and Starkova, J. (2012) Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically. Cancer Lett. 319, 144-153
38. Schlottmann, S., Erkizan, H. V., Barber-Rotenberg, J. S., Knights, C., Cheema, A., Uren, A., Avantaggiati, M. L. and Toretsky, J. A. (2012) Acetylation increases EWS-FLI1 DNA binding and transcriptional activity. Front. Oncol. 2, 107
39. Xie, H. J., Noh, J. H., Kim, J. K., Jung, K. H., Eun, J. W., Bae, H. J., Kim, M. G., Chang, Y. G., Lee, J. Y., Park, H. and Nam, S. W. (2012) HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS ONE 7, e34265
40. Jung, K. H., Noh, J. H., Kim, J. K., Eun, J. W., Bae, H. J., Xie, H. J., Chang, Y. G., Kim, M. G., Park, H., Lee, J. Y. and Nam, S. W. (2012) HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J. Cell. Biochem. 113, 2167-2177
41. Gupta, M., Han, J. J., Stenson, M., Wellik, L. and Witzig, T. E. (2012) Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 26, 1356-1364
42. Kanno, K., Kanno, S., Nitta, H., Uesugi, N., Sugai, T., Masuda, T., Wakabayashi, G. and Maesawa, C. (2012) Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells. Oncol. Rep. 28, 867-873
43. Hayashi, A., Horiuchi, A., Kikuchi, N., Hayashi, T., Fuseya, C., Suzuki, A., Konishi, I. and Shiozawa, T. (2010) Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int.J. Cancer. 127, 1332-1346
44. Leggatt, G. R. and Gabrielli, B. (2012) Histone deacetylase inhibitors in the generation of the anti-tumour immune response. Immunol. Cell Biol. 90, 33-38
45. Pecuchet, N., Cluzeau, T., Thibault, C., Mounier, N. and Vignot, S. (2010) Histone deacetylase inhibitors: highlight on epigenetic regulation. Bull. Cancer 97, 917-935
46. Suzuki, K., Oneyama, C., Kimura, H., Tajima, S. and Okada, M. (2011) Down-regulation of the tumor suppressor C-terminal Src kinase (Csk)-binding protein (Cbp)/PAG1 is mediated by epigenetic histone modifications via the mitogen-activated protein kinase (MAPK)/phosphatidylinositol 3-kinase (PI3K) pathway. J. Biol. Chem. 286, 15698-15706
47. Banik, D., Khan, A. N., Walseng, E., Segal, B. H. and Abrams, S. I. (2012) Interferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity. PLoS ONE 7, e45422
48. Kurundkar, D., Srivastava, R. K., Chaudhary, S. C., Ballestas, M. E., Kopelovich, L., Elmets, C. A. and Athar, M. (2012) Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol. Appl. Pharmacol. 266, 233-244
49. Richon, V. M., Sandhoff, T. W., Rifkind, R. A. and Marks, P. A. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S. A. 97, 10014-10019
50. Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z., Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B. and Grant, S. (1999) Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18, 7016-7025
51. Al-Yacoub, N., Fecker, L. F., Mobs, M., Plotz, M., Braun, F. K., Sterry, W. and Eberle, J. (2012) Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling. J. Invest. Dermatol. 132, 2263-2274
52. Park, J. H., Ahn, M. Y., Kim, T. H., Yoon, S., Kang, K. W., Lee, J., Moon, H. R., Jung, J. H., Chung, H. Y. and Kim, H. S. (2012) A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells. Invest. New Drugs 30, 1887-1898
53. Kang, F. W., Que, L., Wu, M., Wang, Z. L. and Sun, J. (2012) Effects of trichostatin A on HIF-1α and VEGF expression in human tongue squamous cell carcinoma cells in vitro. Oncol. Rep. 28, 193-199
54. Sasakawa, Y., Naoe, Y., Noto, T., Inoue, T., Sasakawa, T., Matsuo, M., Manda, T. and Mutoh, S. (2003) Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem. Pharmacol. 66, 897-906
55. Qian, D. Z., Wang, X., Kachhap, S. K., Kato, Y., Wei, Y., Zhang, L., Atadja, P. and Pili, R. (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 64, 6626-6634
56. Advani, A., Huang, Q., Thai, K., Advani, S. L., White, K. E., Kelly, D. J., Yuen, D. A., Connelly, K. A., Marsden, P. A. and Gilbert, R. E. (2011) Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. Am. J. Pathol. 178, 2205-2214
57. Sidana, A., Wang, M., Shabbeer, S., Chowdhury, W. H., Netto, G., Lupold, S. E., Carducci, M. and Rodriguez, R. (2012) Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. J. Biomed. Biotechnol. 2012, 180363
58. Noro, R., Miyanaga, A., Minegishi, Y., Okano, T., Seike, M., Soeno, C., Kataoka, K., Matsuda, K., Yoshimura, A. and Gemma, A. (2010) Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21waf1/cip1 expression. Cancer Sci. 101, 1424-1430
59. Fakih, M. G., Fetterly, G., Egorin, M. J., Muindi, J. R., Espinoza-Delgado, I., Zwiebel, J. A., Litwin, A., Holleran, J. L., Wang, K. and Diasio, R. B. (2010) A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin. Cancer Res. 16, 3786-3794
60. Iwahashi, S., Ishibashi, H., Utsunomiya, T., Morine, Y., Ochir, T. L., Hanaoka, J., Mori, H., Ikemoto, T., Imura, S. and Shimada, M. (2011) Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. J. Med. Invest. 58, 106-109
61. Konsoula, Z., Cao, H., Velena, A. and Jung, M. (2011) Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity. Int. J. Radiat. Oncol. Biol. Phys. 79, 1541-1548
62. Saelen, M. G., Ree, A. H., Kristian, A., Fleten, K. G., Furre, T., Hektoen, H. H. and Flatmark, K. (2012) Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. Radiat. Oncol. 7, 165
63. Shoji, M., Ninomiya, I., Makino, I., Kinoshita, J., Nakamura, K., Oyama, K., Nakagawara, H., Fujita, H., Tajima, H., Takamura, H. et al. (2012) Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma. Int. J. Oncol. 40, 2140-2146
64. Glenisson, W., Castronovo, V. and Waltregny, D. (2007) Histone deacetylase 4 is required for TGFβ1-induced myofibroblastic differentiation. Biochim. Biophys. Acta 1773, 1572-1582
65. Marumo, T., Hishikawa, K., Yoshikawa, M., Hirahashi, J., Kawachi, S. and Fujita, T. (2010) Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am. J. Physiol. Renal Physiol. 298, F133-F141
66. Pang, M., Ma, L., Liu, N., Ponnusamy, M., Zhao, T. C., Yan, H. and Zhuang, S. (2011) Histone deacetylase 1/2 mediates proliferation of renal interstitial fibroblasts and expression of cell cycle proteins. J. Cell. Biochem. 112, 2138-2148
67. Watanabe, T., Tajima, H., Hironori, H., Nakagawara, H., Ohnishi, I., Takamura, H., Ninomiya, I., Kitagawa, H., Fushida, S., Tani, T. et al. (2011) Sodium valproate blocks the transforming growth factor (TGF)-β1 autocrine loop and attenuates the TGF-β1-induced collagen synthesis in a human hepatic stellate cell line. Int. J. Mol. Med. 28, 919-925
68. Niki, T., Rombouts, K., De Bleser, P., De Smet, K., Rogiers, V., Schuppan, D., Yoshida, M., Gabbiani, G. and Geerts, A. (1999) A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology 29, 858-867
69. Rombouts, K., Knittel, T., Machesky, L., Braet, F., Wielant, A., Hellemans, K., De Bleser, P., Gelman, I., Ramadori, G. and Geerts, A. (2002) Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. J. Hepatol. 37, 788-796
70. Davies, E. R., Haitchi, H. M., Thatcher, T. H., Sime, P. J., Kottmann, R. M., Ganesan, A., Packham, G., O'Reilly, K. M. and Davies, D. E. (2012) Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 46, 687-694
71. Liu, F., Levin, M. D., Petrenko, N. B., Lu, M. M., Wang, T., Yuan, L. J., Stout, A. L., Epstein, J. A. and Patel, V. V. (2008) Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J. Mol. Cell. Cardiol. 45, 715-723
72. Kee, H. J., Sohn, I. S., Nam, K. I., Park, J. E., Qian, Y. R., Yin, Z., Ahn, Y., Jeong, M. H., Bang, Y. J., Kim, N. et al. (2006) Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113, 51-59
73. Bulow, R., Fitzner, B., Sparmann, G., Emmrich, J., Liebe, S. and Jaster, R. (2007) Antifibrogenic effects of histone deacetylase inhibitors on pancreatic stellate cells. Biochem. Pharmacol. 74, 1747-1757
74. Pang, M., Ma, L., Gong, R., Tolbert, E., Mao, H., Ponnusamy, M., Chin, Y. E., Yan, H., Dworkin, L. D. and Zhuang, S. (2010) A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int. 78, 257-268
75. Catania, A., Iavarone, C., Carlomagno, S. M. and Chiariello, M. (2006) Selective transcription and cellular proliferation induced by PDGF require histone deacetylase activity. Biochem. Biophys. Res. Commun. 343, 544-554
76. Klampfer, L., Huang, J., Swaby, L. A. and Augenlicht, L. (2004) Requirement of histone deacetylase activity for signaling by STAT1. J. Biol. Chem. 279, 30358-30368
77. Lee, H. B., Noh, H., Seo, J. Y., Yu, M. R. and Ha, H. (2007) Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy. Kidney. Int. Suppl. S61-S66
78. Yoshikawa, M., Hishikawa, K., Marumo, T. and Fujita, T. (2007) Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-β1 in human renal epithelial cells. J. Am. Soc. Nephrol. 18, 58-65
79. Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P. and Sweet, M. J. (2011) Histone deacetylases as regulators of inflammation and immunity. Trends. Immunol. 32, 335-343
80. Roger, T., Lugrin, J., Le Roy, D., Goy, G., Mombelli, M., Koessler, T., Ding, X. C., Chanson, A. L., Reymond, M. K., Miconnet, I. et al. (2011) Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 117, 1205-1217
81. Nencioni, A., Beck, J., Werth, D., Grunebach, F., Patrone, F., Ballestrero, A. and Brossart, P. (2007) Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin. Cancer. Res. 13, 3933-3941
82. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J., Pulendran, B. and Palucka, K. (2000) Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767-811
83. Reis e Sousa, C. (2004) Activation of dendritic cells: translating innate into adaptive immunity. Curr. Opin. Immunol. 16, 21-25
84. Edens, R. E., Dagtas, S. and Gilbert, K. M. (2006) Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int. Immunopharmacol. 6, 1673-1681
85. Tao, R. and Hancock, W. W. (2007) Regulating regulatory T cells to achieve transplant tolerance. Hepatobiliary Pancreat. Dis. Int. 6, 348-357
86. Kinugasa, F., Yamada, T., Noto, T., Matsuoka, H., Mori, H., Sudo, Y. and Mutoh, S. (2008) Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model. Biol. Pharm. Bull. 31, 1723-1726
87. Kinugasa, F., Nagatomi, I., Nakanishi, T., Noto, T., Mori, H., Matsuoka, H., Sudo, Y. and Mutoh, S. (2009) Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model. Transpl. Immunol. 21, 198-202
88. Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., Yasayko, S. A., Wilkinson, J. E., Galas, D., Ziegler, S. F. and Ramsdell, F. (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27, 68-73
89. Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., Kelly, T. E., Saulsbury, F. T., Chance, P. F. and Ochs, H. D. (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27, 20-21
90. Hori, S., Nomura, T. and Sakaguchi, S. (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061
91. Fontenot, J. D., Gavin, M. A. and Rudensky, A. Y. (2003) Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat. Immunol. 4, 330-336
92. Khattri, R., Cox, T., Yasayko, S. A. and Ramsdell, F. (2003) An essential role for Scurfin in CD4+ CD25+ T regulatory cells. Nat. Immunol. 4, 337-342
93. Wang, L., de Zoeten, E. F., Greene, M. I. and Hancock, W. W. (2009) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat. Rev. Drug Discovery 8, 969-981
94. Tao, R., de Zoeten, E. F., Ozkaynak, E., Chen, C., Wang, L., Porrett, P. M., Li, B., Turka, L. A., Olson, E. N., Greene, M. I. et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13, 1299-1307
95. de Zoeten, E. F., Wang, L., Sai, H., Dillmann, W. H. and Hancock, W. W. (2010) Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 138, 583-594
96. Reilly, C. M., Thomas, M., Gogal, Jr, R., Olgun, S., Santo, A., Sodhi, R., Samy, E. T., Peng, S. L., Gilkeson, G. S. and Mishra, N. (2008) The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J. Autoimmun. 31, 123-130
97. Saouaf, S. J., Li, B., Zhang, G., Shen, Y., Furuuchi, N., Hancock, W. W. and Greene, M. I. (2009) Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 87, 99-104
98. Choi, J. H., Oh, S. W., Kang, M. S., Kwon, H. J., Oh, G. T. and Kim, D. Y. (2005) Trichostatin A attenuates airway inflammation in mouse asthma model. Clin. Exp. Allergy 35, 89-96
99. Mishra, N., Reilly, C. M., Brown, D. R., Ruiz, P. and Gilkeson, G. S. (2003) Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111, 539-552
100. Glauben, R., Batra, A., Fedke, I., Zeitz, M., Lehr, H. A., Leoni, F., Mascagni, P., Fantuzzi, G., Dinarello, C. A. and Siegmund, B. (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176, 5015-5022
101. Nishida, K., Komiyama, T., Miyazawa, S., Shen, Z. N., Furumatsu, T., Doi, H., Yoshida, A., Yamana, J., Yamamura, M., Ninomiya, Y. et al. (2004) Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21WAF1/Cip1 expression. Arthritis Rheum. 50, 3365-3376
102. Lin, H. S., Hu, C. Y., Chan, H. Y., Liew, Y. Y., Huang, H. P., Lepescheux, L., Bastianelli, E., Baron, R., Rawadi, G. and Clement-Lacroix, P. (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150, 862-872
103. Reddy, P., Maeda, Y., Hotary, K., Liu, C., Reznikov, L. L., Dinarello, C. A. and Ferrara, J. L. (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl. Acad. Sci. U.S. A. 101, 3921-3926
104. Li, N., Zhao, D., Kirschbaum, M., Zhang, C., Lin, C. L., Todorov, I., Kandeel, F., Forman, S. and Zeng, D. (2008) HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc. Natl. Acad. Sci. U.S. A. 105, 4796-4801
105. Huang, L. (2006) Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. J. Cell. Physiol. 209, 611-616
106. Medzhitov, R. and Horng, T. (2009) Transcriptional control of the inflammatory response. Nat. Rev. Immunol. 9, 692-703
107. Smale, S. T. (2010) Selective transcription in response to an inflammatory stimulus. Cell 140, 833-844
108. Chen, X., Barozzi, I., Termanini, A., Prosperini, E., Recchiuti, A., Dalli, J., Mietton, F., Matteoli, G., Hiebert, S. and Natoli, G. (2012) Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc. Natl. Acad. Sci. U.S. A. 109, E2865-E2874
109. Usui, T., Okada, M., Mizuno, W., Oda, M., Ide, N., Morita, T., Hara, Y. and Yamawaki, H. (2012) HDAC4 mediates development of hypertension via vascular inflammation in spontaneous hypertensive rats. Am. J. Physiol. Heart. Circ. Physiol. 302, H1894-H1904
110. Grabiec, A. M., Korchynskyi, O., Tak, P. P. and Reedquist, K. A. (2012) Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann. Rheum. Dis. 71, 424-431
111. Wu, C., Li, A., Leng, Y., Li, Y. and Kang, J. (2012) Histone deacetylase inhibition by sodium valproate regulates polarization of macrophage subsets. DNA Cell Biol. 31, 592-599
112. Leoni, F., Zaliani, A., Bertolini, G., Porro, G., Pagani, P., Pozzi, P., Dona, G., Fossati, G., Sozzani, S., Azam, T. et al. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. U.S.A. 99, 2995-3000
113. Segain, J. P., Raingeard de la Bletiere, D., Bourreille, A., Leray, V., Gervois, N., Rosales, C., Ferrier, L., Bonnet, C., Blottiere, H. M. and Galmiche, J. P. (2000) Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease. Gut 47, 397-403
114. Luhrs, H., Gerke, T., Muller, J. G., Melcher, R., Schauber, J., Boxberge, F., Scheppach, W. and Menzel, T. (2002) Butyrate inhibits NF-κB activation in lamina propria macrophages of patients with ulcerative colitis. Scand. J. Gastroenterol. 37, 458-466
115. Furlan, A., Monzani, V., Reznikov, L. L., Leoni, F., Fossati, G., Modena, D., Mascagni, P. and Dinarello, C. A. (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17, 353-362
116. Gray, S. G. and Ekstrom, T. J. (2001) The human histone deacetylase family. Exp. Cell Res. 262, 75-83
117. Nerup, J. and Pociot, F. (2001) A genomewide scan for type 1-diabetes susceptibility in Scandinavian families: identification of new loci with evidence of interactions. Am. J. Hum. Genet. 69, 1301-1313
118. van Tilburg, J. H., Sandkuijl, L. A., Strengman, E., van Someren, H., Rigters-Aris, C. A., Pearson, P. L., van Haeften, T. W. and Wijmenga, C. (2003) A genome-wide scan in type 2 diabetes mellitus provides independent replication of a susceptibility locus on 18p11 and suggests the existence of novel loci on 2q12 and 19q13. J. Clin. Endocrinol. Metab. 88, 2223-2230
119. Mosley, A. L. and Ozcan, S. (2003) Glucose regulates insulin gene transcription by hyperacetylation of histone h4. J. Biol. Chem. 278, 19660-19666
120. Chakrabarti, S. K., Francis, J., Ziesmann, S. M., Garmey, J. C. and Mirmira, R. G. (2003) Covalent histone modifications underlie the developmental regulation of insulin gene transcription in pancreatic β cells. J. Biol. Chem. 278, 23617-23623
121. Christensen, D. P., Dahllof, M., Lundh, M., Rasmussen, D. N., Nielsen, M. D., Billestrup, N., Grunnet, L. G. and Mandrup-Poulsen, T. (2011) Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol. Med. 17, 378-390
122. Mosley, A. L., Corbett, J. A. and Ozcan, S. (2004) Glucose regulation of insulin gene expression requires the recruitment of p300 by the β-cell-specific transcription factor Pdx-1. Mol. Endocrinol. 18, 2279-2290
123. Evans-Molina, C., Garmey, J. C., Ketchum, R., Brayman, K. L., Deng, S. and Mirmira, R. G. (2007) Glucose regulation of insulin gene transcription and pre-mRNA processing in human islets. Diabetes 56, 827-835
124. Qiu, Y., Guo, M., Huang, S. and Stein, R. (2002) Insulin gene transcription is mediated by interactions between the p300 coactivator and PDX-1, BETA2, and E47. Mol. Cell. Biol. 22, 412-420
125. Qiu, Y., Sharma, A. and Stein, R. (1998) p300 mediates transcriptional stimulation by the basic helix-loop-helix activators of the insulin gene. Mol. Cell. Biol. 18, 2957-2964
126. Mosley, A. L. and Ozcan, S. (2004) The pancreatic duodenal homeobox-1 protein (Pdx-1) interacts with histone deacetylases Hdac-1 and Hdac-2 on low levels of glucose. J. Biol. Chem. 279, 54241-54247
127. Lenoir, O., Flosseau, K., Ma, F. X., Blondeau, B., Mai, A., Bassel-Duby, R., Ravassard, P., Olson, E. N., Haumaitre, C. and Scharfmann, R. (2011) Specific control of pancreatic endocrine β- and δ-cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9. Diabetes 60, 2861-2871
128. Chou, D. H., Holson, E. B., Wagner, F. F., Tang, A. J., Maglathlin, R. L., Lewis, T. A., Schreiber, S. L. and Wagner, B. K. (2012) Inhibition of histone deacetylase 3 protects β cells from cytokine-induced apoptosis. Chem. Biol. 19, 669-673
129. Lewis, E. C., Blaabjerg, L., Storling, J., Ronn, S. G., Mascagni, P., Dinarello, C. A. and Mandrup-Poulsen, T. (2011) The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro. Mol. Med. 17, 369-377
130. Susick, L., Senanayake, T., Veluthakal, R., Woster, P. M. and Kowluru, A. (2009) A novel histone deacetylase inhibitor prevents IL-1β induced metabolic dysfunction in pancreatic β-cells. J. Cell. Mol. Med. 13, 1877-1885
131. Villeneuve, L. M. and Natarajan, R. (2010) The role of epigenetics in the pathology of diabetic complications. Am. J. Physiol. Renal. Physiol. 299, F14-F25
132. Crosson, C. E., Mani, S. K., Husain, S., Alsarraf, O. and Menick, D. R. (2010) Inhibition of histone deacetylase protects the retina from ischemic injury. Invest. Ophthalmol. Visual Sci. 51, 3639-3645
133. Zhang, J., Henagan, T. M., Gao, Z. and Ye, J. (2011) Inhibition of glyceroneogenesis by histone deacetylase 3 contributes to lipodystrophy in mice with adipose tissue inflammation. Endocrinology 152, 1829-1838